Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells.

ABSTRACT: BACKGROUND:Current chemotherapies for Burkitt lymphoma (BL) have dramatically improved its clinical outcome. However, chemoresistance can lead to chemotherapy failure and very poor prognosis; thus, novel strategies are urgently required for patients with drug-resistant BL. To investigate the mechanisms underlying drug resistance in BL, we established drug-resistant BL cell lines: HS-Sultan/ADM (adriamycin-resistant), HS-Sultan/VCR (vincristine-resistant), HS-Sultan/DEX (dexamethasone-resistant), and HS-Sultan/L-PAM (melphalan-resistant). METHODS:Drug transporter and survival factor expression were investigated the using western blotting and real time polymerase chain reaction. Cell survival was analyzed by trypan blue dye exclusion method. RESULTS:The established cell lines acquired cross-

SUBMITTER: Tabata M 

PROVIDER: S-EPMC7076888 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature